Clinical burden and healthcare resource utilization associated with managing sickle cell disease with recurrent vaso-occlusive crises in France
Patients with SCD with recurrent VOCs in France have substantial clinical complications, mortality, and HCRU despite currently available treatment options. Innovative treatments that reduce frequency of or eliminate VOCs are needed to alleviate the burden associated with SCD.
Authors
- Nadia Quignot (ORCID: https://orcid.org/0000-0001-8718-1307)
- Nanxin Li (ORCID: https://orcid.org/0009-0006-4412-0997)
- Jessica Baldwin
- C. Udeze (ORCID: https://orcid.org/0009-0002-7840-6804)
- Giancarlo Pesce (ORCID: https://orcid.org/0000-0003-4925-6325)
- Frederic Galactéros (ORCID: https://orcid.org/0000-0003-2029-8126)
- Lyes Boulmerka
- Heng Jiang (ORCID: https://orcid.org/0000-0003-0170-4715)
- Lila Dahal
Institutions
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1080/03007995.2024.2421287
- Citations
- 1
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.44
Funders
- Vertex Pharmaceuticals